Literature DB >> 12509765

Targeting tumours with genetically enhanced T lymphocytes.

Michel Sadelain1, Isabelle Rivière, Renier Brentjens.   

Abstract

The genetic modification of T lymphocytes is an important approach to investigating normal T-cell biology and to increasing antitumour immunity. A number of genetic strategies aim to increase the recognition of tumour antigens, enhance antitumour activities and prevent T-cell malfunction. T cells can also be engineered to increase safety, as well as to express markers that can be tracked by non-invasive imaging technologies. Genetically modified T cells are therefore proving to be of great value for basic immunology and experimental immunotherapy.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12509765     DOI： 10.1038/nrc971

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  194 in total

1.  Safer CARS.

Authors:  Helen E Heslop
Journal:  Mol Ther       Date:  2010-04       Impact factor: 11.454

Review 2.  Immunotherapy for ovarian cancer: what's next?

Authors:  Lana E Kandalaft; Daniel J Powell; Nathan Singh; George Coukos
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

3.  Simplified process for the production of anti-CD19-CAR-engineered T cells.

Authors:  Barbara Tumaini; Daniel W Lee; Tasha Lin; Luciano Castiello; David F Stroncek; Crystal Mackall; Alan Wayne; Marianna Sabatino
Journal:  Cytotherapy       Date:  2013-08-28       Impact factor: 5.414

4.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

5.  Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.

Authors:  E Liu; Y Tong; G Dotti; H Shaim; B Savoldo; M Mukherjee; J Orange; X Wan; X Lu; A Reynolds; M Gagea; P Banerjee; R Cai; M H Bdaiwi; R Basar; M Muftuoglu; L Li; D Marin; W Wierda; M Keating; R Champlin; E Shpall; K Rezvani
Journal:  Leukemia       Date:  2017-07-20       Impact factor: 11.528

Review 6.  Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

7.  Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy.

Authors:  David M Barrett; Nathan Singh; Xiaojun Liu; Shuguang Jiang; Carl H June; Stephan A Grupp; Yangbing Zhao
Journal:  Cytotherapy       Date:  2014-01-16       Impact factor: 5.414

8.  Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells.

Authors:  Lili Yang; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-09       Impact factor: 11.205

9.  Bcl-2 overexpression enhances tumor-specific T-cell survival.

Authors:  Jehad Charo; Steven E Finkelstein; Navrose Grewal; Nicholas P Restifo; Paul F Robbins; Steven A Rosenberg
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

10.  Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.

Authors:  Xiao-Song Zhong; Maiko Matsushita; Jason Plotkin; Isabelle Riviere; Michel Sadelain
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.